TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05350969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDR132L
Description: CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDR132L
Description: CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to CDR132L
Description: Placebo to CDR132L
Study: NCT04876352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)
Description: Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb/handwriting exercises in a real setting (RS-training)
Description: Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Only baseline evaluations, without longitudinal assessment
Study: NCT06159335

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-Fluciclovine radiotracer
Description: Participants will receive PET radiotracer and MRI
Study: NCT06434246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulley system exercise regimen
Description: The warm-up consists of gentle stretching and basic mobility exercises to prepare the muscles and joints for the activity. Following this, the main segment of the session involves specific exercises using the pulley system, designed to target and improve motor function, strength, and coordination of the upper limbs. The therapist will adjust the exercises according to each child's individual abilities and progression over time. The session concludes with a cool-down period involving light activities and relaxation techniques to ensure a gradual return to baseline physiological states.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy program for CP
Description: Participants in the control group will attend physical therapy sessions twice per week. These sessions aim to maintain or improve physical functioning and manage the symptoms of cerebral palsy. Each session lasts approximately 45 to 60 minutes, These sessions include a variety of therapeutic exercises tailored to each child's needs but do not include the use of the pulley system. Typical activities might involve stretching, strengthening exercises, and manual therapy techniques to enhance joint mobility and muscle function.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physical therapy program for CP
Description: Participants in the control group will attend physical therapy sessions twice per week. These sessions aim to maintain or improve physical functioning and manage the symptoms of cerebral palsy. Each session lasts approximately 45 to 60 minutes, These sessions include a variety of therapeutic exercises tailored to each child's needs but do not include the use of the pulley system. Typical activities might involve stretching, strengthening exercises, and manual therapy techniques to enhance joint mobility and muscle function.
Study: NCT06071741

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
Study: NCT05251116

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre
Description: FreeStyle Libre 2 continuous Glucose Monitoring System
Study: NCT04693780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured guide
Description: Structured guide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: List
Description: List
Study: NCT06363019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting at-risk Mothers Across perinatal period: a Randomized controlled Trial (SMART) mobile application
Description: The intervention is delivered through the SMART mobile application. It contains educational information in audio, visual, article format; on parenting, pregnancy and managing emotional well-being. There is also a peer support feature where participants can speak to experienced mothers via the SMART app. There is also a forum feature where participants can interact with other mothers.
Study: NCT06230731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation
Description: Measure oxygen levels in 5 proximal colon mucosa locations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation
Description: Measure oxygen levels in 5 proximal colon mucosa locations.
Study: NCT05360407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using mobile information application about before and after surgery
Description: The mobile application had three sections: Information forum (I), Personal forum (notebook and reminder) (II) and Ask the Researcher (messaging) (III). The information forum (Figure 2) is a section that enables patients to access related articles, pictures, and videos. The personal forum is a section that allows patients to create their notes and use the necessary reminders. Ask the researcher section allows patients to communicate with the researcher via messages.~The participants could download the mobile application with the name Breast Cancer Surgery Information Guide from the Google Play Store and install it on their phones. Users who were authenticated by the researcher were able to access the content with an e-mail and password.
Study: NCT06010212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
Description: Phase Ib: Patients with advanced ESCC will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 9-18 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~fruquintinib: 3 mg, 4 mg, or 5 mg qd p.o., 2 weeks and 1 week, every 3 weeks ( dose exploration phases were performed sequentially from the 4 mg group, refer to the study design section for specific protocols); Camrelizumab: 200 mg I.V D1, every 3 weeks for treatment cycles; Paclitaxel liposomes: 135 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles; Nidaplatin: 70 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles. Chemotherapy is used for up to 6 cycles, followed by maintenance therapy with fruquintinib + Camrelizumab until disease progression or intolerable toxicity.~Phase II: Up to a total of 30 patients with advanced ESCC will be enrolled.
Study: NCT05371561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reusable respirators
Description: Dentist wearing reusable respirator will examin the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reusable respirators
Description: Dentist wearing reusable respirator will examin the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reusable respirators
Description: Dentist wearing reusable respirator will examin the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reusable respirators
Description: Dentist wearing reusable respirator will examin the patient
Study: NCT05454813

Intervention type: DEVICE
Group type: OTHER
Intervention: Wetness Sensing System Validation
Description: Participants will use the Wetness Sensing System in a simulated setting in the sitting, supine and side position (participants are randomized to either the left or right side position).
Study: NCT05450913

Intervention type: DRUG
Group type: OTHER
Intervention: Priformis intramuscular injection with %2 lidocain
Description: Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
Study: NCT05311020

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pitaya Ovule Extract Drink
Description: consume 1 bottle per day
Study: NCT04917614

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Transcutaneous Electrical Acupoint Stimulation
Study: NCT04894097

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: radial extracorpeal shock wave
Description: Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radial extracorpeal shock wave
Description: Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
Study: NCT04920266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Cap, running and fitness exercisers only
Description: Bottle cap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sweat Patch, all subjects- running, fitness, cycling
Description: Regional contralateral forearm patch

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reference sweat patch, all subjects - running, fitness, cycling
Description: Regional contralateral forearm patch

Intervention type: OTHER
Group type: OTHER
Intervention: Bottle Scale, all subjects - running, fitness, cycling
Description: Bottle weight
Study: NCT05792098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous dilatational tracheostomy (PDTS)
Description: Tracheostomy made by percutaneous dilatational technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous dilatational tracheostomy (PDTS)
Description: Tracheostomy made by percutaneous dilatational technique

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound examination
Description: Ultrasound verification of guidewire position

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopic control of guidewire position

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopic control of guidewire position
Study: NCT06249997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leniolisib
Description: The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.
Study: NCT05838963

Intervention type: DIAGNOSTIC_TEST
Intervention: CTQ-SSS scores
Description: The CTQ-SSS is a self-reported questionnaire that measures the severity of symptoms related to carpal tunnel syndrome, including pain, numbness, tingling, and weakness in the hand and wrist.~Participants in this study will complete the CTQ-SSS and other functional measures that include:~1. demographic information~2. hand dominance~3. Boston Carpal Tunnel Questionnaire (BCTQ)~4. nerve conduction studies (NCS) to measure median nerve conduction velocity (NCV), distal motor latency (DML), and sensory nerve action potential (SNAP) amplitude, Compound muscle action potential (CMAP) amplitude.~5. Hand grip strength~Outcomes will be measured at baseline, 3 months, 6 months, and 12 months.~The primary outcome will be progression to carpal tunnel release surgery, and logistic regression models will be used to assess the predictive value of baseline CTQ-SSS scores for this outcome, adjusted for potential confounding factors such as age, sex, and baseline symptom severity.
Study: NCT06509399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care package
Description: Before the patients in the application group started to be observed, the nurses working in the clinic were trained about the risk assessment, skin assessment, incontinence management, nutrition assessment, positioning, support surfaces and injuries caused by the devices in the BP content to be used in the prevention of IU. After the trainings given to the nurses were completed, care was given to the patients in the practice group in accordance with BP. In addition, patient information was collected from patient information files, nurse observation forms and hospital automation system. In the evaluation step, full compliance with the 7 compliance steps specified in the BP was sought. If any one of these parameters was incomplete, the others were considered as incomplete.~The patients in the control group were followed up for 30 days until the determined number of patients was reached and their data were collected.
Study: NCT04239131

Intervention type: OTHER
Group type: OTHER
Intervention: Skin prick test
Description: a Skin prick test is planned in all patients
Study: NCT04917614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Transcutaneous Electrical Acupoint Stimulation
Study: NCT05231343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual Mini-fragment Plating
Description: Patients randomized to dual mini-fragment plating will undergo clavicle fixation using any configuration of 2.0-mm, 2.4-mm and 2.7-mm limited contact dynamic compression (LC-DCP), locking compression (LCP) or reconstruction plates (i.e., 2.4-mm superior and 2.7-mm anteroinferior). One of the two plates used must be a LC-DCP or LCP plate. Surgeons will contour the mini-fragment plate intraoperatively to fit each patient's anatomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Precontoured Plating
Description: Patients randomized to a single plate construct will undergo fixation using an anatomically precontoured (superior or anterior-inferior) clavicle plate.
Study: NCT05927792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation (continuous theta-burst stimulation)
Description: Participants in intervention group will receive cTBS over the left M1for 5 consecutive days. The detailed parameters as follows: 80% of resting motor threshold (RMT), 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repeated transcranial magnetic stimulation
Description: The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
Study: NCT04970121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition.
Study: NCT06201039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Lidocaine Hydrochloride
Description: Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
Study: NCT06422000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 30 mg/kg given over 6 hours daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
Study: NCT05400577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Description: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Study: NCT03429777

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HearMe Smartphone Application
Description: The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HearMe Smartphone Application
Description: The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
Study: NCT05549492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.
Study: NCT06066411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Ball
Description: The massage ball application will be applied to the patients by the researcher for 20 minutes every day for 3 days.
Study: NCT04707664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
Study: NCT05689242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
Study: NCT05135676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded CGM
Description: A masked CGM sensor will be worn

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time CGM
Description: An unmasked CGM sensor will worn
Study: NCT05337098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.